Trial Profile
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary) ; Doxorubicin
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Endometrial cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 11 Mar 2021 Results of a expansion cohort of a phase I study published in the Investigational New Drugs
- 26 Sep 2018 Results assessing overall survival from expansion cohort of phase Ib trial in relapsed SCLC patients presented at the 19th World Conference on Lung Cancer
- 24 Sep 2018 According to a PharmaMar media release, data was presented at the World Congress of the International Association for the Study of Lung Cancer (IASLC 2018), in Toronto.